/
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ( MRS ), and proprietary biomarkers to optimize clinical treatments. Aclarion s technology addresses the $134.5B U.S. low back and neck pain market, which according to a 2020 JAMA (Journal of the American Medical Association) article is now the most costly healthcare condition in the United States.
The business is unprofitable at the operating level (-9312.55% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 65.6% YoY with margins expanding 2744.7pp.
Negative free cash flow of -$7M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$78K
▲ +65.6% YoY
Net Income (TTM)
-$8M
▼ -3.4% YoY
Op. Margin
-10975.24%
▲ +2744.7pp YoY
ROIC
-45.64%
▲ +817.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$7M
▼ -36.2% YoY
Op. Cash Flow (TTM)
-$7M
▼ -35.9% YoY
Net Debt
-$19M
Net Cash Position
Cash & Equiv.
$19M
3Y CAGR: +7.8%
Continue Research